iRadimed (NASDAQ:IRMD) Reaches New 12-Month Low – Time to Sell?

iRadimed Corporation (NASDAQ:IRMD) hit a new 52-week low during trading on Friday. The stock traded as low as $76.38 and last traded at $76.81, with a volume of 142,452 shares traded. The stock had previously closed at $85.74.

Trending Headlines about iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Record revenue and year-over-year growth: Third-quarter revenue reached $24.2 million, up 14% from the prior-year period and 18% sequentially. Revenue also exceeded the FactSet consensus estimate of $23.5 million. iRadimed Third Quarter 2026 Financial Results
• Positive Sentiment: Improved profitability: GAAP diluted EPS was $0.51, while non-GAAP diluted EPS was $0.55, up from $0.41 and $0.47, respectively, in the second quarter. Non-GAAP EPS matched analysts’ consensus estimate, while the company maintained a 26.7% net margin and 23.45% return on equity. IRadimed Q3 Earnings and Outlook
• Positive Sentiment: Potential production acceleration: Management expects fourth-quarter revenue of $25 million to $26.5 million and is targeting more than 50% sequential growth in output for its MRidium 3870 infusion pump, supporting a potential path toward a $100 million annual revenue run rate. iRadimed Q4 Revenue Outlook

Wall Street Analyst Weigh In

IRMD has been the topic of several research analyst reports. Weiss Ratings upgraded shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. Needham & Company LLC initiated coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating on the stock. Finally, Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

iRadimed Price Performance

The firm has a market cap of $980.74 million, a PE ratio of 41.01 and a beta of 0.91. The company has a 50 day simple moving average of $85.66 and a 200-day simple moving average of $92.69.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, October 30th. The medical equipment provider reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. The business had revenue of $24.20 million for the quarter, compared to analysts’ expectations of $23.47 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. On average, sell-side analysts predict that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

Insider Activity

In related news, Director Monty K. Allen sold 1,419 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the transaction, the director owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. This trade represents a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Large investors have recently added to or reduced their stakes in the business. Integrity Alliance LLC. purchased a new stake in iRadimed in the 3rd quarter worth approximately $422,000. Bridge City Capital LLC boosted its stake in shares of iRadimed by 36.5% in the 3rd quarter. Bridge City Capital LLC now owns 96,975 shares of the medical equipment provider’s stock worth $8,361,000 after buying an additional 25,932 shares during the last quarter. Inspire Investing LLC grew its position in shares of iRadimed by 13.1% during the 3rd quarter. Inspire Investing LLC now owns 1,421 shares of the medical equipment provider’s stock valued at $123,000 after acquiring an additional 165 shares during the period. Kings Path Partners LLC bought a new position in shares of iRadimed in the third quarter worth approximately $590,000. Finally, Nisa Investment Advisors LLC grew its stake in iRadimed by 49.6% during the third quarter. Nisa Investment Advisors LLC now owns 1,643 shares of the medical equipment provider’s stock valued at $142,000 after acquiring an additional 545 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.